imiquimod has been researched along with Kidney Neoplasms in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Battaglia, F; Boccardo, F; Carmignani, G; Cittadini, G; Criscuolo, D; Fenoglio, D; Ferrera, F; Filaci, G; Indiveri, F; Kalli, F; Murdaca, G; Negrini, S; Parodi, A; Puppo, F; Sciallero, S; Setti, M; Sobrero, A; Tomasello, L; Traverso, P | 1 |
| Fujioka, A; Nakajima, H; Okino, T; Sano, S; Shuin, T; Tarutani, M | 1 |
| Inoue, K; Kamada, M; Karashima, T; Kawada, C; Komatsu, T; Kuroda, N; Niimura, M; Shuin, T; Udaka, K | 1 |
| Arends, TJ; Eisenhardt, A; Falke, J; Lammers, RJ; Pozzi, R; Ravic, M; Rustighini, I; van der Heijden, AG; Vergunst, H; Witjes, JA | 1 |
| Gore, ME; Horton, V; Moore, J; Owens, M; Savage, P; Witt, P | 1 |
2 trial(s) available for imiquimod and Kidney Neoplasms
| Article | Year |
|---|---|
Pharmacokinetic, Pharmacodynamic, and Activity Evaluation of TMX-101 in a Multicenter Phase 1 Study in Patients With Papillary Non-Muscle-Invasive Bladder Cancer.
Topics: Administration, Intravesical; Aminoquinolines; Antineoplastic Agents; Carcinoma, Renal Cell; Cystoscopy; Dose-Response Relationship, Drug; Female; Humans; Imiquimod; Interleukin 1 Receptor Antagonist Protein; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2015 |
A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily.
Topics: Adult; Aged; Aminoquinolines; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imiquimod; Interferon Inducers; Interferons; Kidney Neoplasms; Male; Melanoma; Middle Aged | 1996 |
3 other study(ies) available for imiquimod and Kidney Neoplasms
| Article | Year |
|---|---|
A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Aminoquinolines; Antigens, Neoplasm; Cancer Vaccines; Cell Proliferation; Combined Modality Therapy; Cytotoxicity, Immunologic; Humans; Imiquimod; Interferon-gamma; Kidney Neoplasms; Male; Mannitol; Middle Aged; Neoplasm Staging; Oleic Acids; Peptides; Phenotype; Prostatic Neoplasms; Telomerase; Treatment Outcome | 2013 |
Effective treatment of metastatic renal cell carcinoma with topical imiquimod therapy.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Imiquimod; Kidney Neoplasms; Male; Middle Aged; Skin Neoplasms; Treatment Outcome | 2014 |
Novel combination therapy with imiquimod and sorafenib for renal cell carcinoma.
Topics: Adenocarcinoma; Aminoquinolines; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Disease Models, Animal; Drug Therapy, Combination; Female; Imiquimod; Kidney Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |